PROPEL is one of the world's largest repositories of patient-derived xenografts (PDXs) for adult and pediatric leukemias. Researchers may request these resources with no obligation to collaborate. PROPEL, an initiative of St. Jude Children's Research Hospital, is designed to accelerate discovery and cures for acute lymphoblastic leukemia and other types of leukemia.
View a list of publications describing the source of samples and their use in research.
> Contain 19 cases with paired Diagnosis-Relapse samples (sequencing pending)
Alexander, T. B., et al. "The genetic basis and cell of origin of mixed phenotype acute leukaemia." Nature 562(7727): 373-379, 2018.
Roberts, K. G., et al. "Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL." Blood Adv 1(20): 1657-1671, 2017.
Iacobucci, I., et al. "Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia." Cancer Cell 29(2): 186-200, 2016.
Gu, Z., et al. "Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia." Nat Commun 7: 13331, 2016.
Zhang, J., et al. "Deregulation of DUX4 and ERG in acute lymphoblastic leukemia" Nat Genet 48(12): 1481-1489, 2016.
Holmfeldt L, Mullighan CG. Generation of Human Acute Lymphoblastic Leukemia Xenografts for Use in Oncology Drug Discovery. Current protocols in pharmacology: John Wiley & Sons, Inc.; 2015.
Churchman, M. L., et al. "Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia." Cancer Cell 28(3): 343-356, 2015.
Maude, S. L., et al. "Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia." Blood 125(11): 1759-1767, 2015.
Roberts, K. G., et al. "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia." N Engl J Med 371(11): 1005-1015, 2014.
Holmfeldt, L., et al. "The genomic landscape of hypodiploid acute lymphoblastic leukemia." Nat Genet 45(3): 242-252, 2013.